Plerixafor

證據等級: L5

預測適應症: 10 個

Plerixafor: From an Unregistered Indication in Denmark to Indolent Plasma Cell Myeloma

One-Sentence Summary

Plerixafor (DrugBank ID: DB06809) has no registered marketing authorisation in Denmark and no original indication or mechanism-of-action data available in this evidence pack. The TxGNN model predicts a possible link to Indolent Plasma Cell Myeloma with a very high prediction score (99.97%), but this prediction is currently supported by 0 clinical trials and 0 publications — it rests on the model output alone.

Quick Overview

Item	Content
Original Indication	Not available — no licenses or original indication data in this evidence pack
Predicted New Indication	Indolent Plasma Cell Myeloma
TxGNN Prediction Score	99.97%
Evidence Level	L5 (model prediction only, no supporting trials or literature)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for plerixafor is not currently available in this evidence pack (flagged as a High-severity data gap), and no original indication is recorded. As a result, the relationship between plerixafor’s established pharmacology and the predicted indication (indolent plasma cell myeloma) cannot be assessed from the data provided here.

The TxGNN model’s repurposing rationale field for this top-ranked prediction is also marked “pending” — no mechanistic-link or similarity-to-original-indication narrative has been generated for it. For comparison, several lower-ranked predictions in this same evidence pack (e.g., melanoma-related indications, bronchitis) do include a CXCR4-CXCL12-axis-based rationale, but these apply to different predicted diseases, not to the top-ranked indolent plasma cell myeloma prediction, and none of them are supported by trial or literature evidence either.

Given the very high model score but complete absence of a documented mechanistic rationale, clinical trials, or literature for this specific top prediction, this should be treated as a pure signal-generation output requiring further mechanistic and clinical validation before any scientific claim can be made.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Plerixafor currently holds no marketing authorisation in Denmark (market status: Not marketed; total licenses on file: 0). No product, dosage form, or approved indication information is available.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. Note: the underlying data source flags the absence of label warnings/contraindications as a Blocking data gap, meaning a safety pre-assessment (S1) cannot currently be completed for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication carries no clinical trial or literature support (Evidence Level L5), the drug’s mechanism of action and original indication are undocumented, and it is not currently marketed in Denmark. A Blocking data gap (missing label warnings/contraindications) also prevents a safety pre-assessment from being completed.

To proceed, the following is needed:

Label warnings and contraindications (e.g., from the manufacturer’s SmPC) to clear the Blocking safety data gap
Confirmed mechanism of action to establish biological plausibility for the indolent plasma cell myeloma prediction
Original indication and regulatory history, to contextualize the repurposing rationale
A dedicated literature and clinical trial search specifically for plerixafor in plasma cell myeloma/multiple myeloma populations
Clarification of Danish/EU regulatory pathway, given the drug currently has zero marketing authorisations on file
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.